ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NMAD / forecast
HRTX (34) BOLD (46) CTOR (34) VRCA (32) ⌘ Pro Terminal →

Nomad Power Solutions Inc. (NMAD) 12-Month Stock Forecast & Price Target Cone

$3.47 -2.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.45

Nomad Power Solutions Inc. (NMAD) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $55.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NMAD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NMAD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nomad Power Solutions Inc. (NASDAQ: NMAD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.47 (-2.53% 1D, market cap $55.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NMAD ranks #766 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NMAD compare to HRTX and BOLD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NMAD carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and BOLD (Boundless Bio Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $56.4M). Among the 5-stock peer group, NMAD leads on earnings multiple (N/A) while NMAD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NMAD?
▼

Per NMAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001335105), Nomad Power Solutions Inc. generated $14.3M in revenue (+43.0% YoY), -$6.1M in net income, and -$3.1M in free cash flow against $12.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.45 (-0.65%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$9 Bull$3 Base$2 Bear
📬 FREE NMAD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NMAD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY NMAD SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$4.28-13.1% Next Q
Q2 (-2Q)
36
Grade E$3.72+5.9% Next Q
Q3 (-1Q)
34
Grade E$3.94-11.9% Next Q
Current
31
Grade E$3.47-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NMAD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NMAD currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.85) and Max Pain ($3.64) forces dealer call-delta covering toward $8.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NMAD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NMAD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NMAD Position Size: $10,000

Shares at $3.47: 2881.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $2.38
$6,859
$-3,141 (-31.4%)
12M Consensus BaseTarget $3.05
$8,790
$-1,210 (-12.1%)
12M Bull Case BreakoutTarget $8.80
$25,360
+$15,360 (+153.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$374%A
Goldman SachsSector Coverage LeadUNDERPERFORM$869%B
JP MorganUS Large-Cap ResearchSELL$358%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NMAD)

  • ✓Walkthrough of NMAD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NMAD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.72%🛡️ HOLDING TREND SUPPORT
2026-11-04O $3.56H $3.56L $3.47C $3.47VOL 281.2K
RES: $4.70SUP: $3.21SMA50: $3.85SMA200: $4.26
$8.75$7.22$5.69$4.16$2.64RES $4.70SUP $3.21$3.472026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NMAD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NMAD Butterfly Map → + Track NMAD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +43.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NMAD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NMAD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NMAD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NMAD)

Health Care Rank #766 of 1015 ⚔️ HRTX vs NMAD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NMAD vs. HRTX, BOLD, CTOR, VRCA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nomad Power Solutions Inc. (NMAD) ranks #766 by composite RQD confidence (31/100, grade E) and #724 by equity capitalization ($55.9M). Within this direct 5-issuer industry benchmark cohort, NMAD leads on earnings valuation at N/A trailing P/E, while NMAD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BOLD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NMAD at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NMAD ACTIVE
Nomad Power Solutions Inc.
E 31/100 — — -35.0% -2.53% $55.9M Benchmark Subject
HRTX
Heron Therapeutics Inc.
E 34/100 — 73.3% -35.0% +6.27% $56.0M /hrtx-vs-nmad →
BOLD
Boundless Bio Inc.
D 46/100 — — -35.0% -1.22% $56.4M /bold-vs-nmad →
CTOR
Citius Oncology Inc.
E 34/100 — — -35.0% +7.24% $55.2M /ctor-vs-nmad →
VRCA
Verrica Pharmaceuticals Inc.
E 32/100 — — -35.0% -4.18% $55.1M /vrca-vs-nmad →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001335105 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nomad Power Solutions Inc. (NMAD) reported GAAP revenue of $14.3M (+43.0% vs. FY2024 revenue of $10.0M , and +0.3% cumulative change since FY2023) , GAAP net income of -$6.1M, operating cash flow of -$3.1M, and free cash flow of -$3.1M (+3.0% YoY). On the balance sheet, NMAD closed FY2025 with $12.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $14.3M -$6.1M -$3.1M -$3.1M $12.7M —
FY2024 (FY) 2024-12-31 $10.0M -$3.6M -$3.2M -$3.2M $1.1M —
FY2023 (FY) 2023-12-31 $14.3M -$5.1M -$4.3M -$4.3M — —

3. NMAD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NMAD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nomad Power Solutions Inc. (NASDAQ: NMAD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.47 (-2.53% 1D, market cap $55.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NMAD ranks #766 in composite RQD confidence.

How does NMAD compare to HRTX and BOLD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NMAD carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $56.0M) and BOLD (Boundless Bio Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $56.4M). Among the 5-stock peer group, NMAD leads on earnings multiple (N/A) while NMAD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NMAD?

Per NMAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001335105), Nomad Power Solutions Inc. generated $14.3M in revenue (+43.0% YoY), -$6.1M in net income, and -$3.1M in free cash flow against $12.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NMAD trading relative to its 50-day, 200-day, and 52-week technical levels?

NMAD last traded at $3.47 (-2.53% on volume of 281,163 shares), positioning the stock -9.87% below its 50-day simple moving average ($3.85) and -18.54% below its 200-day simple moving average ($4.26). Across its 52-week range of $2.36 to $8.38, NMAD sits at the 18.4% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.04 to $3.90).

Direct Sub-Reports: NMAD RQD Cockpit NMAD 12M Forecast NMAD Earnings & Move NMAD Dividends & DRIP NMAD Insiders & 13F NMAD Whale Options NMAD Profit Sankey NMAD News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

NMAD — Nomad Power Solutions Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nomad Power Solutions Inc. (NMAD) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.47 (-2.53% 1D, market capitalization $55.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -5.39%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nomad Power Solutions Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Recent news items describe customer orders and sales reach, but these are headlines without financial detail in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nomad Power Solutions Inc. (NMAD) reported $14.3M in annual revenue (up from $10.0M in FY2024, +43.0% YoY) and -$6.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.3M revenue, -$5.1M net income) through FY2025, NMAD scaled operating cash flow to -$3.1M and free cash flow to -$3.1M, backed by $12.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.39% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.36 – $8.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be mapped from source data. Sector correlations are not provided beyond the Health Care classification. A prospective investor should watch whether the reported customer orders and manufacturing expansion convert into revenue, since that conversion is the only identifiable second-order link in the source data and it is not verifiable here.

  • Key Question #1: Can NMAD sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $14.3M and free cash flow of -$3.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NMAD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NMAD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nomad Power Solutions Inc. (NMAD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NMAD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NMAD Bull vs. Bear Conversation Board — What's Your Call at $3.47?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NMAD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NMAD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $4.34 (+21.9%)
📌 Pinned Debate

Headlines report more than $30 million in customer orders and expanded manufacturing capacity, a potential catalyst if it converts to r

Picked up a starter position in NMAD in my $100K Virtual Cash book at $3.56. Headlines report more than $30 million in customer orders and expanded manufacturing capacity, a potential catalyst if it converts to revenue.. Trading inside a $2.36–$8.38 52-week range with -5.39% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@BreakoutHunter Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.56 and keeping dry powder in case we test $3.31.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.81 (-21.1%)
Spot @ $3.56

The company reported $0.0M revenue and negative free cash flow in each of FY 2023–FY 2025 with an RQD score of 33 (E).

The company reported $0.0M revenue and negative free cash flow in each of FY 2023–FY 2025 with an RQD score of 33 (E).. Look at the math on NMAD: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $3.13 before getting long.

LIVE TAPE